EGFR
MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients
Genomics Data 2016 June 20 [Link] Lin RC, Kirschner MB, Cheng YY, van Zandwijk N, Reid G Abstract Malignant pleural mesothelioma (MPM) is a tumor originating in the mesothelium, the membrane lining the thoracic cavities, and is induced by exposure to asbestos. Australia suffers one of the world’s highest rates of MPM and the incidence…
Read MoreEffect of renal function on pemetrexed-induced haematotoxicity
Cancer, chemotherapy, and pharmacology [Epub ahead of print] [ Link] Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K, Yamaguchi T, Funatsu M, Ikeda Y, Imaizumi K, Kawada K, Yasuda K, Yamada S. Abstract PURPOSE: Pemetrexed (PEM) is an anticancer agent used for the treatment of non-small cell lung cancer, malignant pleural…
Read MoreUse of Quality Metrics for a New Hypo-Fractionated Pre-Surgical Mesothelioma Protocol
Medical Physics 2015 June [Link] Richardson S, Mehta V. Abstract Purpose The “SMART” (Surgery for Mesothelioma After Radiation Therapy) approach involves hypo-fractionated radiotherapy of the lung pleura to 25Gy over 5 days followed by surgical resection within 7. Early clinical results suggest that this approach is very promising, but also logistically challenging due to the…
Read MoreTargeted therapies in malignant pleural mesothelioma: a review of clinical studies
Anticancer Drugs. 2011 Mar;22(3):199-205. [Link] Greillier L, Marco S, Barlesi F. Service d’Oncologie Multidisciplinaire et Innovations Thérapeutiques, Université de la Méditerranée-Assistance Publique Hôpitaux de Marseille, Marseille, France. Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, whose exposure to asbestos fibers is the main etiology. The incidence of MPM is anticipated to…
Read MoreTargeted inhibition of multiple receptor tyrosine kinases in mesothelioma
Neoplasia. 2011 Jan;13(1):12-22. [Link] Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA. Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA. Abstract The receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR) and MET are activated in subsets of mesothelioma, suggesting that these kinases might represent novel therapeutic…
Read MoreSummary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer
Journal of Thoracic Oncology. 2011 Jan 4. [Epub ahead of print] [Link] KaoSubramanian J, Corrales L, Soulieres D, Morgensztern D, Govindan R. *Division of Oncology, Department of Medicine, Washington University School of Medicine; †Department of Medicine, Alvin J Siteman Cancer Center at Washington University School of Medicine, St Louis, Missouri; and ‡Department of Medicine, Centre…
Read MoreNovel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma
Annals of Surgical Oncology. 2009 Jan;16(1):152-8. Epub 2008 Nov 8. [Link] Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW. Division of Surgical Oncology, Creighton University Medical Center, Creighton University, Omaha, NE 68131, USA. jasonfoster@creighton.edu Abstract Malignant peritoneal mesotheliomas (MPM) are rare tumors representing 20% of all malignant mesothelioma cases. The median survival for…
Read MoreSystemic Treatments for Mesothelioma: Standard and Novel
Current Treatment Options in Oncology. 2008 Jun;9(2-3):171-9. Epub 2008 Sep 3. [Link] Kindler HL. Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA. hkindler@medicine.bsd.uchicago.edu Abstract Systemic therapy is the only treatment option for the majority of mesothelioma patients, for whom age, co-morbid medical illnesses, non-epithelial histology, and locally advanced disease often preclude surgery. For…
Read MoreThe serine protease HtrA1 is a novel prognostic factor for human mesothelioma
Pharmacogenomics. 2008 Aug;9(8):1069-77. [Link] Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, Di Marino M, di Crescenzo VG, Visca P, Menegozzo S, Spugnini EP, Citro G, Ceribelli A, Mirri A, Chien J, Shridhar V, Ehrmann M, Santini M, Facciolo F. Department of Biochemistry and Biophysics, Section of Pathology, Second University of Naples, Via…
Read MoreEpidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma
Journal of Cancer Research and Clinical Oncology. 2008 Apr 8 [Epub ahead of print] [Link] Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Science, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. Abstract Epidermal growth factor receptor…
Read More